AMLN
Amylin Pharmaceuticals LLC
%Change: N/ACurrent Volume: N/A
AMLN is currently neutral.
P/E: N/AMarket Cap: N/A
52 Week High: N/A
52 Week Low: N/A
Next Year EPS: N/A
GOOG AAPL AMZN NFLX BIIB CELG COST WFM AMGN ALXN ULTA ONXX TSLA FFIV SBAC GMCR VRTX
MDY IBM LNKD V IVV SPY GS UNP DIA PXD EOG GLD ACT CVX LQD TIP CMI MCK TLT PX
New Highs! BA DOV FMC WDC SNPS LPS BR HPQ P
MDY IBM LNKD V IVV SPY GS UNP DIA PXD EOG GLD ACT CVX LQD TIP CMI MCK TLT PX
New Highs! BA DOV FMC WDC SNPS LPS BR HPQ P
| AMLN is currently neutral. |
|
Watchlist:
CVX IJH NBL WHR MDY RL VFC SPG IVV SPY PSA GS UNP PPG DIA PXD WYNN BLK BIIB ACT BA DOV FMC WDC SNPS LPS HPQ P BR
Amylin Pharmaceuticals, Inc. (Amylin) is a biopharmaceutical company focusing on the diabetes and other metabolic diseases through the discovery, development and commercialization of medicines. It markets two medicines to treat diabetes, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. It is also markets a diabetes treatment, BYDUREON (exenatide extended-release for injectable suspension). BYDUREON is an extended-release medication for type 2 diabetes that provides continuous glycemic control in a once-weekly dose. Amylin maintains a research and early development program focused on peptide and protein therapeutics. It has also entered into alliances and business initiatives, including its relationship with Biocon, Limited (Biocon) to develop pharmaceutical products, including AC165198, a peptide hybrid drug candidate for diabetes, which was developed from its phybrid technology platform. In August 2012, Bristol-Myers Squibb Company acquired the Company.
 |